ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

317
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
06 Jan 2025 09:04

Insignia Financial (IFL AU): CC Capital Wades In With A $4.30/Share NBIO

Terms are non-binding. I think IFL should engage here. However, I'm not confident Tanarra is willing to kick out at a 7.5% premium to Bain's terms.

Logo
445 Views
Share
bullishVesync
06 Jan 2025 02:14

Merger Arb Mondays (06 Jan) - Vesync, Canvest, Get Nice, Fosun Tourism, GAPack, HKBN, Seven & I

This week, the highest gross spreads are Seven & I (15.0%), Get Nice Financial (11.6%),  Arcadium Lithium (11.0%), ESR (8.9%), Goldlion (7.3%),...

Logo
726 Views
Share
bullishViva Goods
03 Jan 2025 12:21

Bossini (592 HK): 10th Feb Scheme Vote

The spread is there and Viva is shortable.  Not sure if you can take down borrow cheaply. Otherwise, this is an avoid. Viva is trading rich. It may...

Logo
668 Views
Share
03 Jan 2025 10:27

Get Nice Financial (1469 HK): EGM Set For Get Nice (64 HK)'s Scrip Offer

The more interesting bet is GNH (64 HK) at a 74% discount to NAV and 0.21x P/B, which will (should) be taken out next. That may be worth a punt.

Logo
691 Views
Share
bullishESR Group
02 Jan 2025 06:15

(Mostly) Asia M&A, Dec 2024: De Grey, Insignia, ESR Group, Fosun Tourism, HKBN, Pentamaster, Beenos

For Dec 2024, 13 new transactions were discussed on Smartkarma with an overall deal size of ~US$16bn. The Dec average premium for these new...

Logo
705 Views
Share
x